Rangaswamy Govindarajan, MD
Full Member
Research Program:
Cancer Therapeutics
Faculty Rank:
Professor
Campus:
University of Arkansas for Medical Sciences
College:
College of Medicine
Department:
Internal Medicine
|
Cancer Research Interest
- Disease Site Focus: GI, Sarcoma
- Research Focus Area: Informatics, Treatment, Diagnosis/ Prognosis
- Type of Research: Clinical
Contact Information
- Email Address: GOVINDARAJANRANG@UAMS.EDU
- Profiles Research Networking Software: View Profile
Open Clinical Trials
- “A Phase 2, Single-Arm, Open-Label Study with Dostarlimab Monotherapy in Participants with Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer” (NCT05723562)
- “A221805 Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study” (NCT04137107)
Active Grants
- Alliance for Clinical Trials in Oncology – A021806“A PHASE III TRIAL OF PERIOPERATIVE VERSUS ADJUVANT CHEMOTHERAPY FOR RESECTABLE PANCREATIC CANCER (273375)”Principal Investigator10/22/21 – 10/21/31
Publications
- Algazi AP, Othus M, Daud AI, [et al., including Govindarajan R]. Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Nature medicine. 2020 26(10):1564-1568. PMID: 33020646. PMCID: PMC8063889.
- Van Tine BA, Govindarajan R, Attia S, [et al.]. Incidence and Management of Olaratumab Infusion-Related Reactions. Journal of oncology practice. 2019 15(11):e925-e933. PMID: 31268811. PMCID: PMC6851793.
- Atwal D, Safar AM, Govindarajan R, Makhoul I. Severe first infusion reaction related to cetuximab in cancer patients in Arkansas. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2019 25(5):1130-1134. PMID: 29890919.